Yoshie Y, Iizuka K, Nakazawa T
First Department of Internal Medicine, Gunma University School of Medicine, Japan.
J Asthma. 1988;25(6):321-4. doi: 10.3109/02770908809071373.
To study the possible role of alpha-2 receptors in intractable asthmatics, we investigated the ameliorative effects of 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylthyl]pyridine dihydrochloride sesquihydrate (DG-5128) on 10 steroid-dependent asthmatic patients. The forced expiratory volume in 1 second (FEV1) and the respiratory resistance (Rrs) were measured 1, 2, and 3 hours after oral administration of 200 mg DG-5128 and compared with the premedication measurements. Two hours after DG-5128 administration, the FEV1 rose significantly (p less than 0.01) and the Rrs decreased significantly (p less than 0.05). Asthmatic symptoms (cough, wheezing, dyspnea) also improved in 80% of the patients. This finding raises the possibility that alpha-2 adrenoceptors exist in human airways, that they play an important role in the pathophysiology of asthma, and that the overfunction of these alpha-2 adrenoceptors and/or Gi-protein cause intractable asthma.
为研究α-2受体在难治性哮喘患者中可能发挥的作用,我们调查了2-[2-(4,5-二氢-1H-咪唑-2-基)-1-苯乙基]吡啶二盐酸盐倍半水合物(DG-5128)对10例依赖类固醇的哮喘患者的改善作用。口服200mg DG-5128后1、2和3小时测量1秒用力呼气量(FEV1)和呼吸阻力(Rrs),并与用药前测量值进行比较。给予DG-5128两小时后,FEV1显著升高(p<0.01),Rrs显著降低(p<0.05)。80%的患者哮喘症状(咳嗽、喘息、呼吸困难)也有所改善。这一发现增加了以下可能性:人类气道中存在α-2肾上腺素能受体,它们在哮喘的病理生理学中发挥重要作用,并且这些α-2肾上腺素能受体和/或Gi蛋白功能亢进导致难治性哮喘。